Chiral polymer-induced hydroxyapatite for promoting bone regeneration
Zhang Z., Liang B., Wang D., Zhang Y., Geng Z., Xing D.
Laboratory Study, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Mater Today Bio (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39885944
- PMCID
- PMC11780956
- DOI
- 10.1016/j.mtbio.2025.101460
- Citations
- 4
Abstract (original English)
Chirality is one of the basic characteristics of living matter, yet the effect of chiral polymers on osteogenesis is seldom studied. Thus, it is necessary to deeply recognize the behaviors of chiral polymers in osteogenic processes, which can be beneficial for the development of bone repair materials. In this work, chiral hydroxyapatite (HAP) was constructed simply using poly(levorotatory/dextral-tartaric acid) as the guest of the chiral transfer system. We studied the influence of chiral HAPs on the migration and differentiation of pre-osteoblasts, and angiogenesis of endothelial cell in vitro. The results showed that poly(levorotatory-tartaric acid)-induced HAP did promote vascular remodeling and exhibited excellent impact on osteogenetic differentiation by improving the related gene and protein expression, whereas no significant change was observed in poly(dextral-tartaric acid) or poly(racemic-tartaric acid) induced HAP, respectively. This study highlighted the effects of chiral polymers on osteogenic potential, which laid the groundwork for the development of biomaterials for bone regeneration.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.